Enalapril is an angiotensin-converting enzyme inhibitor used for treatment of hypertension and chronic heart disease. Enalaprilat\nis its active metabolite responsible for the activity. This study aimed to develop and validate a method for enalapril and enalaprilat\nanalysis and to determine the bioequivalence of two tablet formulae of enalapril. LC-MS/MS bioanalytical method was developed\nand validated and then applied to evaluate the bioavailability of two enalapril formulae. Antihyperglycemic sitagliptin was used as\ninternal standard (IS). The method was accurate for the within- and between-days analysis, and precise CV% was <5%, being linear\nover the calibration range 1.0ââ?¬â??200.0 ng/ml. Stability was >85%and the LODwas 0.907 and 0.910 ng/ml for enalapril and enalaprilat,\nrespectively, and LLOQ was 1 ng/ml. The pharmacokinetic parameters
Loading....